SonoScape Medical (SZSE:300633) Shareholders Have Earned a 19% CAGR Over the Last Three Years
SonoScape Medical (SZSE:300633) Shareholders Have Earned a 19% CAGR Over the Last Three Years
SonoScape Medical Corp. (SZSE:300633) shareholders might be concerned after seeing the share price drop 17% in the last quarter. But that shouldn't obscure the pleasing returns achieved by shareholders over the last three years. After all, the share price is up a market-beating 67% in that time.
上個季度股價下跌17%後,SonoScape Medical Corp.(深圳證券交易所股票代碼:300633)的股東可能會感到擔憂。但這不應掩蓋股東在過去三年中獲得的豐厚回報。畢竟,當時股價上漲了67%,超過了市場。
So let's investigate and see if the longer term performance of the company has been in line with the underlying business' progress.
因此,讓我們調查一下,看看公司的長期表現是否與基礎業務的進展一致。
To quote Buffett, 'Ships will sail around the world but the Flat Earth Society will flourish. There will continue to be wide discrepancies between price and value in the marketplace...' One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.
引用巴菲特的話說:“船隻將在世界各地航行,但Flat Earth Society將蓬勃發展。市場上的價格和價值之間將繼續存在巨大差異...”考慮市場對公司的看法發生了怎樣的變化的一種不完美但簡單的方法是將每股收益(EPS)的變化與股價走勢進行比較。
SonoScape Medical was able to grow its EPS at 86% per year over three years, sending the share price higher. The average annual share price increase of 19% is actually lower than the EPS growth. So one could reasonably conclude that the market has cooled on the stock.
SonoScape Medical得以在三年內將其每股收益增長到每年86%,這推動了股價的上漲。19%的年平均股價漲幅實際上低於每股收益的增長。因此,人們可以合理地得出結論,該股市場已經降溫。
The company's earnings per share (over time) is depicted in the image below (click to see the exact numbers).
該公司的每股收益(隨着時間的推移)如下圖所示(點擊查看確切數字)。
![earnings-per-share-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240312/0-9983b2314425148de1cf280d98780de8-0-09913397d966939cbc89820a2eb1130e.png/big)
It is of course excellent to see how SonoScape Medical has grown profits over the years, but the future is more important for shareholders. It might be well worthwhile taking a look at our free report on how its financial position has changed over time.
看到SonoScape Medical多年來如何增加利潤當然是件好事,但對於股東來說,未來更爲重要。可能值得一看我們的免費報告,了解其財務狀況如何隨着時間的推移而變化。
A Different Perspective
不同的視角
We regret to report that SonoScape Medical shareholders are down 18% for the year (even including dividends). Unfortunately, that's worse than the broader market decline of 13%. However, it could simply be that the share price has been impacted by broader market jitters. It might be worth keeping an eye on the fundamentals, in case there's a good opportunity. On the bright side, long term shareholders have made money, with a gain of 6% per year over half a decade. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. Before deciding if you like the current share price, check how SonoScape Medical scores on these 3 valuation metrics.
我們遺憾地報告說,SonoScape Medical的股東今年下跌了18%(甚至包括股息)。不幸的是,這比整個市場13%的跌幅還要嚴重。但是,可能只是股價受到了更廣泛的市場緊張情緒的影響。如果有很好的機會,可能值得關注基本面。好的一面是,長期股東賺了錢,在過去的五年中,每年增長6%。如果基本面數據繼續顯示長期可持續增長,那麼當前的拋售可能是一個值得考慮的機會。在決定是否喜歡當前股價之前,請查看SonoScape Medical在這三個估值指標上的得分情況。
But note: SonoScape Medical may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).
但請注意:SonoScape Medical可能不是最值得購買的股票。因此,來看看這份過去盈利增長(以及進一步增長預測)的有趣公司的免費清單。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.
請注意,本文引用的市場回報反映了目前在中國交易所交易的股票的市場加權平均回報。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。